EMA Authorised: Efficib (sitagliptin;metformin hydrochloride) — Merck Sharp and Dohme B.V

View source ↗

Summary

EMA authorised Efficib, a fixed-dose combination tablet of sitagliptin and metformin for type 2 diabetes mellitus; Merck Sharp & Dohme B.V. is the marketing aut…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Efficib (sitagliptin and metformin hydrochloride)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Merck Sharp and Dohme B.V. Decision date: 27/11/2025